Navigation Links
Experimental Staph Vaccine Fails to Work, Study Finds
Date:4/2/2013

TUESDAY, April 2 (HealthDay News) -- An experimental vaccine does not reduce the risk of staph infections in patients who have had heart or chest surgery, a large new study finds.

The study included more than 7,000 thousand adult cardiothoracic patients. About half of them received an injection of the "V710" vaccine 14 to 60 days before their surgery, while the others received a placebo.

At 90 days after surgery, Staphylococcus aureus infections showed up in 22 of 3,528 vaccinated patients and in 27 of 3,517 patients who received the placebo. No significant differences in effectiveness were ever seen between the vaccine and placebo groups during the study.

The researchers also found that patients who received the vaccine had more negative side effects in the 14 days after vaccination than those who received the placebo (31 percent vs. 22 percent), including serious problems (1.7 percent vs. 1.3 percent).

In addition, patients who received the vaccine were much more likely to suffer multi-organ failure at some point in the study (31 vs. 17 events), according to the study in the April 3 issue of the Journal of the American Medical Association.

The difference in the death rate from all causes was not statistically significant between the groups of patients (201 of 3,958 vs. 177 of 3,967), but the death rate among patients who developed staph infections was much higher among those who received the vaccine (15 of 73 vs. 4 of 96), according to a journal news release.

"These findings do not support the use of the V710 vaccine for patients undergoing surgical interventions," concluded Dr. Vance Fowler Jr., of Duke University Medical Center, and colleagues.

Dr. Preeti Malani, of the University of Michigan Health System, wrote an accompanying journal editorial.

"While the prevention of S. aureus infections should remain a priority for future investigation, novel approaches must move beyond vaccine strategies -- and for that matter, beyond S. aureus. Even if a viable staphylococcal vaccine were to be developed, this would not address non-S. aureus infections," Malani wrote.

More information

The U.S. Centers for Disease Control and Prevention discusses surgical site infections.

-- Robert Preidt

SOURCE: Journal of the American Medical Association, news release, April 2, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug May Work Against Hepatitis C
2. Experimental Alzheimers Drug Shows Promise, Study Finds
3. Experimental Vitiligo Treatment Shows Promise in Mice
4. Harmful effects of bisphenol A proved experimentally
5. Experimental agent briefly eases depression rapidly in test
6. NIH-funded trial launched to assess experimental TB drug
7. Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
8. Experimental Antidepressant Appears Quick-Acting, Safe
9. More than a third of high-risk leukemia patients respond to an experimental new drug
10. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
11. Experimental Insomnia Drug Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Staph Vaccine Fails to Work, Study Finds
(Date:3/23/2017)... ... March 23, 2017 , ... ... help improve all aspects of people’s health and nutrition, announced its product Leyzene ... , Natural Subsistence develops nutritional supplements that help people improve all aspects ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! ... thinking about summer internships , which can be frustrating when they don’t even ... Garden Media Group, a boutique public relations firm outside of Philadelphia, have offered these ...
(Date:3/23/2017)... NC (PRWEB) , ... March 23, 2017 , ... Inflow ... ride). Life is serious so build on a solid foundation. As experts in ... priority vital information that is coming soon. Inflownomics deliver ripe, fresh, clean & refreshing ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is now offering ... Verisys through its FACIS and other services maintains the largest healthcare ... “We are delighted to be able to offer these various products to our ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality ... 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. ... not only to the association, but also to the Health Care Quality and Patient ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... LUND, Sweden , Mar 23, 2017 ... mitochondrial medicine company, today announced that the English version of ... company,s website www.neurovive.com .  ... About NeuroVive NeuroVive Pharmaceutical ... committed to the discovery and development of medicines that preserve ...
(Date:3/23/2017)... Sweden , Mar 23, 2017 The ... notice to the Annual General Meeting, which is to take place ... Scheelevägen 2 in Lund, Sweden . ... Please see the attached notification, ... och Inrikes Tidningar. NeuroVive Pharmaceutical AB (Publ) The Board ...
(Date:3/22/2017)... PUNE, India , March 23, 2017 ... 2017 - 2021, a latest research report. The global ... market is shift of surgeons focus toward minimally invasive ... popular or limited to few developed countries having high ... ...
Breaking Medicine Technology: